Madrigal Pharmaceuticals, Inc. MDGL
Set alert
431.16 USD +0.79 +0.18%
At close
425.00 -6.15 -1.43%
Pre-market · Nov 3, 4:09 AM ET
425.33 Day range 436.74
399.00 52-week range 615.00
- YTD
- -25.96%
- 1 year
- +2.93%
- Open
- 430.04
- Prev close
- 430.36
- Mkt cap
- 9.96B
- Vol
- 495.09K
- Avg vol
- 270.00K
- EPS
- -12.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 425.33
- High
- 436.74
- Forward P/E
- 44.80
- Beta
- -1.00
- Short ratio
- 7.90
- Inst. own
- 104.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 498.66
- 200-d avg
- 499.95
- 1y target
- 685.22
YTD chart
Events in this range
- Feb 19, 2026Earnings: -2.57; estimate 0.04; surprise -6525%
- May 6, 2026Earnings: -3.25; estimate -3.61; surprise 9.97%
- Jun 11, 2026Rating: B of A Securities · Neutral → Neutral
- Jul 27, 2026Rating: Wells Fargo · — → Overweight
- Jul 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Jul 30, 2026Earnings: -1.99; estimate -2.68; surprise 25.75%
- Aug 3, 2026Rating: Barclays · Overweight → Overweight
- Aug 4, 2026Rating: Wolfe Research · Peer Perform → Outperform
- Sep 23, 2026Rating: Citigroup · — → Buy
Signals (45)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
Newest 20 of 45.
Key statistics
- Market cap
- 9.96B
- Enterprise value
- 9.45B
- Trailing P/E
- 0.00
- Forward P/E
- 44.80
- PEG ratio
- 0.00
- Price / sales
- 7.76
- Price / book
- 19.01
- EPS (TTM)
- -12.85
- Beta
- -1.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -25.32%
- Revenue (TTM)
- 1.28B
- Revenue growth
- 71.20%
- Free cash flow
- -80.47M
- Total cash
- 838.75M
- Total debt
- 347.75M
- Return on equity
- -53.31%
- Shares outstanding
- 23.10M
- Short % of float
- 11.17%
- 50-day average
- 498.66
- 200-day average
- 499.95
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 685.22 +58.9% upside
Now 431.16
- Target (low)
- 533.00
- Target (mean)
- 685.22
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -1.09.
Financials — quick view
MDGL Revenue — quarterly 364.25M
MDGL Net income — quarterly -57.94M
MDGL EPS — quarterly -1.99
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.86294 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -2.68 | -1.99 | +0.69 | +25.75% |
| May 6, 2026 | Mar 31, 2026 | -3.61 | -3.25 | +0.36 | +9.97% |
| Feb 19, 2026 | Dec 31, 2025 | 0.04 | -2.57 | -2.61 | -6,525.00% |
| Nov 4, 2025 | Sep 30, 2025 | -2.04 | -5.08 | -3.04 | -149.38% |
| Aug 5, 2025 | Jun 30, 2025 | -3.48 | -1.90 | +1.58 | +45.40% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Aug 4, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | main | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | init | — | Overweight |
| Jun 11, 2026 | B of A Securities | main | Neutral | Neutral |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- madrigalpharma.com
News
- Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know
- Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
- Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra
Your note
Sign in to keep a note on MDGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Unknown | Stock Award(Grant) | Jun 16, 2026 | 0 |
| CRAVES FREDERICK B | Director | Sale | Mar 12, 2025 | 383,547 |
| DIER MARDI C | Chief Financial Officer | Sale | Mar 5, 2026 | 12,490 |
| FRIEDMAN PAUL A | Director | Sale | Jan 8, 2026 | 842,704 |
| HUNTSMAN CAROLE A | Officer | Sale | Mar 5, 2026 | 12,692 |
| KELLEY SHANNON T | General Counsel | Sale | Aug 16, 2026 | 11,474 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.28% | 2,143,131 | 924.02M | Jun 29, 2026 |
| RTW Investments LP | 8.63% | 1,993,687 | 859.59M | Jun 29, 2026 |
| Jupiter Topco LLC | 8.38% | 1,936,099 | 834.76M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.94% | 1,833,333 | 790.45M | Jun 29, 2026 |
| PAULSON & CO. INC. | 5.80% | 1,340,020 | 577.76M | Jun 29, 2026 |
| Blackrock Inc. | 5.20% | 1,200,770 | 517.72M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.53% | 584,997 | 252.22M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.44% | 563,117 | 242.79M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.83% | 423,142 | 182.44M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.47% | 338,602 | 145.99M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17% | 270,288 | 116.54M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.05% | 243,683 | 105.07M | Jun 29, 2026 |